January 07, 2025 06:26 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Delhi assembly elections on Feb 5, results on Feb 8 | Allu Arjun visits boy injured during Pushpa 2 stampede in Hyderabad | Donald Trump repeats his US-Canada merger offer after Justin Trudeau's resignation | India's HMPV cases surge to 7 after two cases reported from Nagpur | H-1B visa renewal will get simpler in 2025, Indians to benefit most as home country travel won't be required | As India detects 3 HMPV cases, #lockdown trends; Centre says no need to panic | Justin Trudeau announces resignation as Canada's PM amid rising pressure by partymates | 8 jawans, driver killed as Maoists blow up security vehicle in Chhattisgarh's Bijapur | Atul Subhash suicide: Karnataka High Court refuses to quash FIR against wife Nikita Singhania | Delhi elections: Congress launches Pyari Didi scheme promising Rs. 2,500 per month to women residents
Two doses of India's COVAXIN is 50 percent effective against symptomatic COVID-19: Study

Two doses of India's COVAXIN is 50 percent effective against symptomatic COVID-19: Study

Nov 24, 2021, at 03:23 pm

New Delhi: The first real-world assessment of BBV152, a COVID-19 vaccine developed in India, known as COVAXIN in the country, suggests that two vaccine doses result in 50 percent effectiveness against symptomatic COVID-19.